Piridoxina Clorhidrato Sanderson

Piridoxina Clorhidrato Sanderson Hydrochloride is used for isoniazid-induced peripheral neuritis, idiopathic sideroblastic anaemia and Vitamin B₆ deficiency states.

For isoniazid-induced peripheral neuritis

For idiopathic sideroblastic anaemia

For deficiency states

Hypersensitivity to any of the ingredients.

If symptoms persist or worsen, seek medical advice. Do not exceed the stated dose.

None known.

Long term administration of large doses of Piridoxina Clorhidrato Sanderson is associated with the development of severe peripheral neuritis.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

a) Symptoms - None reported

b) Treatment - no treatment necessary.

Piridoxina Clorhidrato Sanderson hydrochloride is Vitamin B₆. It is converted to pyridoxal phosphate which is the co-enzyme for a variety of metabolic transformations. It is essential for human nutrition.

Piridoxina Clorhidrato Sanderson hydrochloride is absorbed from the gastrointestinal tract and is converted to the active forms pyridoxal phosphate and pyridoxamine phosphate. It crosses the placental barrier and appears in breast milk. It is excreted in the urine as 4-pyridoxic acid.

There are no preclinical data of relevance to the prescriber, which are additional to those already included in other sections of the Summary of Product Characteristics.

None known

Not applicable.